decitabine + autologous DC-CIK cells

Decitabine + autologous DC-CIK cells is a combination chemo-immunotherapy regimen being investigated as a post-remission maintenance treatment for malignant solid tumors. The regimen consists of the hypomethylating agent decitabine followed by the infusion of autologous dendritic cell-cytokine induced killer (DC-CIK) cells. Decitabine, a DNA methyltransferase inhibitor, is administered at low doses to induce epigenetic changes in tumor cells, such as the upregulation of tumor-associated antigens and MHC molecules, which sensitizes the tumor to immune-mediated destruction. DC-CIK cells are a heterogeneous population of immune effector cells, primarily CD3+CD56+ T cells, that are expanded ex vivo with cytokines and pulsed with dendritic cells to enhance their tumor-specific targeting and cytotoxic activity. This combination therapy aims to leverage the epigenetic priming of decitabine to improve the efficacy of adoptive cell transfer in patients with solid tumors.

Other names

decitabine enhanced DC-CIKdecitabine-Li Yu-malignant solid tumor